-
Mashup Score: 3New biomarker data from the Phase 3 trial, presented at the Gordon Research Conference - 10 month(s) ago
Top …
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering - 10 month(s) ago
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the “Company”), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer - 10 month(s) ago
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ –…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0
Skip to content …
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 2
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update - 2 year(s) ago
BrainStorm to request Type A meeting with FDA to facilitate NurOwn’s advancement following receipt of a refusal to file letter regarding the company’s new Biologics License Application Conference…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update - 2 year(s) ago
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company’s randomized,…
Categories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 1BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update - 2 year(s) ago
BrainStorm to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for NurOwn® for the treatment of ALS New clinical analyses reinforce the conclusions from…
Categories: Latest Headlines, Rare DiseaseTweet
Can anyone help me with the n=23 on the causal inference description on the poster (left column, 3/4 way down), please? Thanks for any enlightenment. https://t.co/1kqpFAYLpa